Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
GMED Stock Chart & Stats
$87.81
$2.66(3.19%)
At close: 4:00 PM EST
$87.81
$2.66(3.19%)
Day’s Range― - ―
52-Week Range$51.79 - $101.40
Previous CloseN/A
Volume442.39K
Average Volume (3M)1.68M
Market Cap
$11.86B
Enterprise Value$11.47B
Total Cash (Recent Filing)$557.24M
Total Debt (Recent Filing)$118.66M
Price to Earnings (P/E)21.9
Beta0.82
Next Earnings
May 12, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding112,625,130
10 Day Avg. Volume1,610,796
30 Day Avg. Volume1,684,810
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit5.79
Enterprise Value/Ebitda14.04
Forecast
1Y Price Target
$108.54Price Target Upside23.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)4.39
Revenue Forecast (FY)$3.20B
Bulls Say, Bears Say
Bulls Say
Acquisition Integration And Product PipelineAnalyst points to successful integration of the Nevro acquisition and record enabling technology revenue, with a surgical robot development pipeline offering additional growth and diversification.
Margin Expansion And Earnings GuidanceAnalyst notes management raised adjusted earnings guidance after margin improvement, indicating the company can convert revenue growth into stronger profitability.
U.S. Spine Market ShareAnalyst highlights accelerating U.S. spine sales driven by higher procedure volumes, rep conversions, and product launches, positioning Globus Medical to capture market share above peers.
Bears Say
Enabling Technology Adoption And Lease MixAnalyst warns that a heavy lease mix and slower adoption of enabling technologies such as robotics could flatten revenue growth for the enabling technology segment.
International Operations And Franchise TransitionsAnalyst flags lagging international operations and ongoing franchise transitions as headwinds that could dampen overall group revenue until execution improves.
Operating Expense And Valuation PressureAnalyst cautions that rising operating expenses and current valuation levels may limit upside by constraining margin expansion and leaving limited room for multiple expansion.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $51.79 and its highest was $101.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $11.86B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is May 12, 2026 which is in 63 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Feb 24, 2026. The company reported $1.28 earnings per share for the quarter, beating the consensus estimate of $1.134 by $0.146.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 0.9.
How many shares outstanding does Globus Medical have?
Globus Medical has 112,625,130 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $1.28 in its last earnings report, beating expectations of $1.134. Following the earnings report the stock price went up 4.724%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$108.54 (23.61% Upside)
$108.54 (23.61% Upside)
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.82%
12-Months-Change
Fundamentals
Return on Equity
10.01%
Trailing 12-Months
Asset Growth
0.19%
Trailing 12-Months
Company Description
Globus Medical
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
GMED Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive picture: strong top- and bottom-line growth, record Q4 results, margin expansion, rapid synergy realization (NuVasive synergies ahead of plan), and earlier-than-expected accretion from Nevro. Management raised EPS guidance and reaffirmed revenue guidance for 2026 while outlining plans for continued R&D investment and capital placement flexibility. Offsetting these positives were early-year operational and Enabling Tech lumpiness, international supply chain and regional challenges, integration risk for Nevro, a meaningful decline in the cash balance due to acquisitions, debt paydown and buybacks, and temporary one-time charges. Overall, the highlights (robust revenue and profit growth, margin improvement, successful synergy capture, and raised guidance) outweigh the lowlights, which are largely short- to medium-term execution and integration issues.View all GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$108.54
▲(23.61% Upside)
Technical Analysis
Boston Scientific
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.72% Insiders
32.97% Mutual Funds
25.20% Other Institutional Investors
18.81% Public Companies and Individual Investors